ClinicalTrials.Veeva

Menu

Multicenter Real-World Study of Hyperthermia in Warts of Special Population

C

China Medical University

Status

Enrolling

Conditions

Warts

Treatments

Device: YY-WRY-V01 Infrared thermotherapy apparatus

Study type

Interventional

Funder types

Other

Identifiers

NCT06827938
AF-SOP-07-1.2-01

Details and patient eligibility

About

Hyperthermia refers to treating diseases with temperatures beyond normal body temperature (39-45℃), and moxibustion therapy of traditional Chinese medicine belongs to the category of hyperthermia. It has been reported at home and abroad that the local temperature of 44℃ can effectively mobilize the body's immunity and remove HPV infection lesions, such as condyloma acuminatum and verruca vulgaris. Our research group conducted randomized controlled experiments on patients with viral warts in the early clinical practice, and the cure rate of the hyperthermia group reached 45-55%, which was superior to the traditional method in the aspects of no trauma, low recurrence rate, easy to tolerate and so on. Our research group's preliminary research on hyperthermia of viral warts has been included in the British Medical Association's guidelines for viral warts therapy. The equipment our research group developed has been obtained the medical device registration certificate, and is in the process of national promotion. Hyperthermia is to mobilize systemic immunity through local warm heat, the preliminary clinical study of the research group shows that the therapeutic effect of hyperthermia is usually "all or none": "all" that is, after hyperthermia, all viral warts are removed, including non-treatment lesions;"None" means that some patients with viral warts do not respond to hyperthermia. Cellular immunity plays a very important role in the removal of warts. At present, some special clinical patients such as pregnant women, children, patients with autoimmune diseases, diabetes, immunosuppressants after organ transplantation and other patients with skin/mucosal HPV infection, their warts show more extensive proliferation or a longer and repeated course of disease, treatment resistance, etc. It has increased the difficulty of clinical treatment, and the specific mechanism is still unclear. Therefore, for these special populations, how to further enhance the therapeutic effect of hyperthermia is the top priority of current research.

In view of the above findings, this research group intends to study the efficacy and safety of hyperthermia in the treatment of viral warts in the special population (pregnant women, children, patients with autoimmune diseases, diabetes, and immunosuppressants after organ transplantation, etc.) in a multicenter real-world study of skin/mucosal HPV infection in the special population.

Enrollment

400 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Pregnant women with viral warts
  2. Diagnosis of AIDS with viral warts
  3. Autoimmune disease patients with viral warts
  4. Diabetic patients with viral warts
  5. Patients with viral warts who are currently being treated with immunosuppressants
  6. Children with viral warts
  7. The subject or legal guardian is able to understand and sign the informed consent/consent to participate in the study

Exclusion criteria

  1. The subject suffers from tumor or other serious disease and cannot complete this clinical study
  2. Timely treatment and follow-up cannot be guaranteed due to personal or other objective reasons

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

400 participants in 1 patient group

Hyperthermia group
Other group
Description:
Infrared hyperthermia(44±1℃) device for 3 consecutive days (times / day), each treatment for 30 minutes After 7-10 days, the lesions of the same target were treated continuously for 2 days (times / day), and then treat every 7-10 days, the method was the same as before. Lesion changes were assessed after 15 treatments.
Treatment:
Device: YY-WRY-V01 Infrared thermotherapy apparatus

Trial contacts and locations

1

Loading...

Central trial contact

Wei Huo, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems